CCNB1

G2/mitotic-specific cyclin-B1 · P14635 · CCNB1 on Sugi Atlas →

133,531 patent compounds predicted against CCNB1, 85,087 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Kenpaullone (SCHEMBL79889)	1.00	19/20
Aloisine (SCHEMBL79714)	1.00	17/20
Aloisine A (SCHEMBL80147)	1.00	17/20
Methylguanine (SCHEMBL34851)	0.51	17/20
SCHEMBL135690	0.51	13/20
Thioguanine (SCHEMBL183648)	0.51	12/20
2,6-Diaminopurine (SCHEMBL24053)	0.54	10/20
Guanine (SCHEMBL122461)	0.51	10/20
Alvocidib (SCHEMBL3651)	1.00	9/20
Alvocidib (SCHEMBL3652)	1.00	9/20
SCHEMBL144954	0.76	9/20
SCHEMBL19840	0.51	9/20
SCHEMBL25860	0.44	9/20
2,6-Diaminopurine (SCHEMBL160630)	0.36	9/20
SCHEMBL19938	0.54	8/20
SCHEMBL159110	0.46	8/20
6-O-Benzylguanine (SCHEMBL61740)	1.00	7/20
Hymenialdisine (SCHEMBL155899)	0.74	7/20
SCHEMBL12292	0.59	7/20
SCHEMBL12466	0.57	7/20

Clinical trials — most relevant to CCNB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	PHASE2/PHASE3	NOT_YET_RECRUITING
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma	PHASE2	COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer	PHASE2	COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies	PHASE1	RECRUITING
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma	PHASE1	WITHDRAWN
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets	PHASE1	UNKNOWN
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	PHASE1	COMPLETED
Tamoxifen in Patients With Oesophageal Cancer	PHASE1	UNKNOWN
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer	PHASE1	UNKNOWN
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CCNB1 binder may also engage these)

Protein	Name	Similarity
Q08301	—	0.998	Q08301 →
P30277	—	0.998	P30277 →
P37882	—	0.994	P37882 →
P24860	—	0.992	P24860 →
Q1LZG6	—	0.992	Q1LZG6 →
O77689	—	0.943	O77689 →
Q4R7A8	—	0.941	Q4R7A8 →
P37883	—	0.937	P37883 →
CCNB2	G2/mitotic-specific cyclin-B2	0.933	landscape →
Q60FY0	—	0.933	Q60FY0 →
B0VX69	—	0.931	B0VX69 →
G3V6U9	—	0.930	G3V6U9 →
B5FW36	—	0.928	B5FW36 →
Q9JK91	—	0.927	Q9JK91 →
Q91WC0	—	0.926	Q91WC0 →
A9X1D0	—	0.926	A9X1D0 →
E2RBS6	—	0.925	E2RBS6 →
Q92162	—	0.925	Q92162 →
Q60FX9	—	0.925	Q60FX9 →
B2KI88	—	0.924	B2KI88 →
C1FXW2	—	0.924	C1FXW2 →
Q86TU7	—	0.924	Q86TU7 →
B7ZUF3	—	0.923	B7ZUF3 →
P40692	—	0.923	P40692 →
B1MTJ4	—	0.922	B1MTJ4 →
P30276	—	0.922	P30276 →
Q5ZML9	—	0.921	Q5ZML9 →
P97679	—	0.921	P97679 →
Q5ZLS7	—	0.920	Q5ZLS7 →
Q7SXS7	—	0.920	Q7SXS7 →